Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study
- PMID: 16448520
- DOI: 10.1111/j.1463-1326.2005.00499.x
Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study
Abstract
Aim: To determine the effects of pioglitazone treatment combined with insulin on glucose and lipid metabolism in patients with type 2 diabetes.
Methods: In a multicentre, double-blind study, 690 patients [body mass index, 33.19 kg/m2 +/- 5.47; haemoglobin A1c (A1C), 9.78 +/- 1.51; mean duration, 12.9 years] with diabetes poorly controlled with a stable insulin dose (> 30 U/day for > or =30 days) were randomly allocated to pioglitazone 30 or 45 mg once daily for 24 weeks.
Results: In the pioglitazone 30- and 45-mg groups, respectively, 71 and 70% of patients completed the study. At 24 weeks, statistically significant, dose-dependent mean decreases from baseline were seen in the pioglitazone 30- and 45-mg groups for A1C (-1.17 and -1.46%, respectively) and fasting plasma glucose (-31.9 and -45.8 mg/dl, respectively). Insulin dosage also decreased significantly (-4.5 and -7.3 U, respectively; p < or = 0.05) from baseline. Decreases in triglycerides [pioglitazone 45 mg: -5.9% (p < or = 0.05)], very low-density lipoprotein cholesterol [pioglitazone 45 mg: -6.2% (p < or = 0.05)] and free fatty acids [-0.94 (p < or = 0.05) and -2.13 (p < 0.0001) mg/dl, respectively] and increases in high-density lipoprotein cholesterol (9.7 and 13.0%, respectively; p < 0.0001) also were observed from baseline. Small but significant increases in total and low-density lipoprotein cholesterol (p < 0.01) from baseline were observed. Mean weight gain was 2.9 and 3.4 kg in the respective groups; lower limb oedema was reported in 13 and 12% of patients, respectively. The incidences of oedema, weight gain and heart failure were not higher than anticipated in this population. No evidence of hepatotoxicity or clinically significant elevations in liver function test parameters was seen.
Conclusions: In patients with poorly controlled type 2 diabetes, addition of pioglitazone to insulin significantly improved glycaemic control, had a positive effect on important components of the lipid profile in a dose-dependent manner and was generally well tolerated.
Similar articles
-
Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.Int J Clin Pract. 2002 May;56(4):251-7. Int J Clin Pract. 2002. PMID: 12074206 Clinical Trial.
-
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.Diabetes Care. 2006 May;29(5):1016-23. doi: 10.2337/diacare.2951016. Diabetes Care. 2006. PMID: 16644631 Clinical Trial.
-
A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.Diabet Med. 2005 Apr;22(4):399-405. doi: 10.1111/j.1464-5491.2004.01426.x. Diabet Med. 2005. PMID: 15787663 Clinical Trial.
-
Pharmacokinetics and clinical efficacy of pioglitazone.Int J Clin Pract Suppl. 2001 Sep;(121):19-25. Int J Clin Pract Suppl. 2001. PMID: 11594240 Review.
-
Current treatment of insulin resistance in type 2 diabetes mellitus.Int J Clin Pract Suppl. 2000 Oct;(113):54-62. Int J Clin Pract Suppl. 2000. PMID: 11965833 Review.
Cited by
-
Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.Drugs. 2010 Oct 22;70(15):1945-61. doi: 10.2165/11538100-000000000-00000. Drugs. 2010. PMID: 20883052 Review.
-
Efficacy of pioglitazone on glycemic control and carotid intima-media thickness in type 2 diabetes patients with inadequate insulin therapy.J Diabetes Investig. 2011 Jan 24;2(1):56-62. doi: 10.1111/j.2040-1124.2010.00064.x. J Diabetes Investig. 2011. PMID: 24843462 Free PMC article.
-
Which is the eligible patient to be treated with pioglitazone? The expert view.J Endocrinol Invest. 2011 Nov;34(10):781-7. doi: 10.1007/BF03346725. J Endocrinol Invest. 2011. PMID: 22234178
-
Pioglitazone in diabetic kidney disease: forgotten but not gone.Arch Med Sci Atheroscler Dis. 2022 Aug 8;7:e78-e93. doi: 10.5114/amsad/151046. eCollection 2022. Arch Med Sci Atheroscler Dis. 2022. PMID: 36158067 Free PMC article.
-
Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study.J Diabetes Res. 2015;2015:834903. doi: 10.1155/2015/834903. Epub 2015 Apr 28. J Diabetes Res. 2015. PMID: 26060825 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical